HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: db07-0720av1 57/3/627    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brands, K. Articles by Tuch, B. E Search for Related Content PubMed PubMed Citation Articles by Brands, K. Articles by Tuch, B. E Related Collections Related Article Social Bookmarking                What's this?

Reduced Immunogenicety of First Trimester Human Fetal Pancreas

¹Diabetes Transplant Unit, The Prince of Wales Hospital and The University of New South Wales, Sydney, Australia
²Departments of Physiology & Pharmacology and Medicine, University of Western Ontario, London, Canada
³Leukaemia Biology Program, Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia

Objective: The use of human fetal pancreatic tissue may provide a potential source of transplantable β-cells as a therapy for type 1 diabetes. Human fetal pancreas has a remarkable capacity to grow and differentiate in vivo and has been shown to reverse diabetes in rodents. However it is known that human fetal pancreas obtained from the 2^nd trimester of gestation is immunogenic and is rejected after transplantation. Tissue obtained from earlier stages might prove to be immune privileged, as has been shown for other tissues.

Research Design and Methods: In this study we determined the immunogenicity of human fetal pancreatic tissue obtained from the 1^st trimester of gestation in a humanized mouse model. A microarray study of immunoregulatory gene expression in 1^st and 2^nd trimester human fetal pancreas was also undertaken.

Results: The analysis of transplanted human fetal pancreata revealed a significantly decreased immunogenicity of the 1^st trimester tissue. The 1^st trimester grafts showed only limited cellular infiltration and contained numerous insulin positive cells, whereas 2^nd trimester tissue was completely infiltrated and rejected. Furthermore an analysis of immunoregulatory genes expressed in 1^st and 2^nd trimester human fetal pancreas by microarray demonstrated the upregulation of several key immunoregulatory genes in the 2nd trimester tissue. This might account for the reduced immunogenicity of the younger tissue.

Conclusions: Our results provide the first indication that the use of 1^st trimester human fetal pancreas for transplantation might increase the survival of the grafts and might decrease the requirement for immunosuppressive drugs.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

First-Trimester Human Fetal Pancreas Transplantation for Type 1 Diabetes Treatment: An Alternative Approach for Achieving Long-Term Graft Survival?

Georgia Fousteri and Matthias von Herrath
Diabetes 2008 57: 525-526. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				G. Fousteri and M. von Herrath First-Trimester Human Fetal Pancreas Transplantation for Type 1 Diabetes Treatment: An Alternative Approach for Achieving Long-Term Graft Survival? Diabetes, March 1, 2008; 57(3): 525 - 526. [Full Text] [PDF]